Scarica l'app Stockscreener
62.51
1.28%
-0.81
Dopo l'orario di chiusura:
62.90
0.39
+0.62%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Jefferies raises Cytokinetics stock price target to $90 on ACACIA study - Investing.com UK
How Cytokinetics Incorporated stock trades before earnings2025 Volume Leaders & Momentum Based Trading Ideas - ulpravda.ru
Is Cytokinetics Incorporated stock attractive for long term wealth building2025 Institutional Moves & High Accuracy Trade Alerts - ulpravda.ru
Is Cytokinetics Incorporated stock attractive for hedge fundsQuarterly Portfolio Summary & Safe Entry Trade Reports - ulpravda.ru
Is Cytokinetics Incorporated stock a good choice for value investorsWeekly Investment Report & Step-by-Step Swing Trade Plans - ulpravda.ru
Can Cytokinetics Incorporated stock deliver consistent earnings growthPortfolio Value Summary & Risk Controlled Stock Alerts - ulpravda.ru
What makes Cytokinetics Incorporated stock attractive to growth fundsIPO Watch & AI Based Trade Execution Alerts - ulpravda.ru
Risk Analysis: Can Cytokinetics Incorporated stock reach $100 price targetMarket Performance Recap & Expert Curated Trade Ideas - ulpravda.ru
Can Cytokinetics Incorporated stock maintain growth trajectoryInsider Selling & Daily Profit Focused Screening - ulpravda.ru
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
How Aficamten REMS Disclosure Probe Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance
Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Insider Sell: Andrew Callos Sells 15,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Sells $904,200.00 in Stock - MarketBeat
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Tango Therapeutics Appoints Sung Lee to Board of Directors - GlobeNewswire Inc.
Cytokinetics (NASDAQ:CYTK) EVP Sells $112,590.76 in Stock - MarketBeat
Callos, Cytokinetics EVP, sells $112,584 in stock By Investing.com - Investing.com South Africa
Callos, Cytokinetics EVP, sells $112,584 in stock - Investing.com India
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, ... - Bluefield Daily Telegraph
Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed - ts2.tech
Cytokinetics, Incorporated (CYTK) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next - ts2.tech
Moody Aldrich Partners LLC Buys Shares of 82,460 Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Stock Soars: What’s Next? - StocksToTrade
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing - ts2.tech
Cytokinetics (NASDAQ:CYTK) Trading 3% HigherStill a Buy? - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Top Cytokinetics Insider Just Cashed Out in a High-Profile Stock Move - TipRanks
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,809 Shares of Stock - MarketBeat
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. ... - Bluefield Daily Telegraph
Notice to Long-Term Shareholders of Alexandria Real Estate - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
What Does the Market Think About Cytokinetics Inc? - Benzinga
Why Is Edgewise Therapeutics Stock Soaring Wednesday? - Benzinga
Cytokinetics FY2025 EPS Forecast Reduced by HC Wainwright - MarketBeat
Squarepoint Ops LLC Has $608,000 Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail
Insider Sell: Wendell Wierenga Sells 20,000 Shares of Cytokineti - GuruFocus
Cytokinetics (NASDAQ:CYTK) Director Sells $1,322,800.00 in Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Cytokinetics Insider Sold Shares Worth $1,322,800, According to a Recent SEC Filing - marketscreener.com
Morgan Stanley Maintains Overweight Rating on CYTK, Raises PT to $71 | CYTK Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
Citizens Maintains Cytokinetics (CYTK) Market Outperform Recommendation - Nasdaq
RBC Capital Maintains Cytokinetics (CYTK) Outperform Recommendation - Nasdaq
Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK) - Seeking Alpha
Cytokinetics Earnings Boost After FDA Approval - StocksToTrade
Cytokinetics’ Breakthrough: Stock Set for Big Gains? - StocksToTrade
FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS Med - MedCity News
Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes - ts2.tech
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM - BioWorld MedTech
Investors Buy Large Volume of Cytokinetics Call Options (NASDAQ:CYTK) - MarketBeat
Cytokinetics jumps after FDA approves its drug for rare heart disease - TradingView — Track All Markets
Cytokinetics Surges as FDA Grants Approval for Myqorzo - timothysykes.com
Why Is Cytokinetics Stock Soaring Monday?Cytokinetics (NASDAQ:CYTK) - Benzinga
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up - Finviz
UniFirst, Adeia, Cytokinetics And Other Big Stocks Moving Higher On Monday - Benzinga
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):